{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon+Alpha", "query": { "intervention": "Interferon Alpha" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 315, "total_pages": 32, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon+Alpha&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T13:47:07.820Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00217373", "title": "Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm" ], "interventions": [ { "name": "Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine", "type": "BIOLOGICAL" }, { "name": "Recombinant Interferon Alfa-2b", "type": "BIOLOGICAL" }, { "name": "Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2005-06", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2015-04-20", "last_synced_at": "2026-09-09T13:47:07.820Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217373" }, { "nct_id": "NCT02174172", "title": "A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Interferon alfa-2b", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "PEG-interferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2014-08-18", "completion_date": "2019-11-25", "has_results": false, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-09-09T13:47:07.820Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02174172" }, { "nct_id": "NCT00004231", "title": "Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "teniposide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-10", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-09-09T13:47:07.820Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004231" }, { "nct_id": "NCT00126594", "title": "Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Recurrent Renal Cell Carcinoma", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Recombinant Interferon Alfa-2b", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2005-06", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-09-16", "last_synced_at": "2026-09-09T13:47:07.820Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00126594" }, { "nct_id": "NCT00028275", "title": "Gamma Interferon Therapy for Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Gamma Interferon 1b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20, "start_date": "2001-12", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-09T13:47:07.820Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028275" }, { "nct_id": "NCT00861406", "title": "Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Pegylated Interferon-Alfa 2b (PEG Intron)", "type": "DRUG" }, { "name": "GP-100 Peptide Vaccine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2009-03-10", "completion_date": "2017-02-24", "has_results": false, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-09-09T13:47:07.820Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861406" }, { "nct_id": "NCT00008463", "title": "A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Interferon alfa-2a", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 132, "start_date": "2000-11", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-09T13:47:07.820Z", "location_count": 24, "location_summary": "San Diego, California • San Francisco, California • Aurora, Colorado + 12 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00008463" }, { "nct_id": "NCT02407080", "title": "Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Polycythemia Vera", "Essential Thrombocythemia" ], "interventions": [ { "name": "RG7388", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Mascarenhas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2015-04", "completion_date": "2018-12-19", "has_results": false, "last_update_posted_date": "2019-09-12", "last_synced_at": "2026-09-09T13:47:07.820Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • New York, New York • Winston-Salem, North Carolina", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02407080" }, { "nct_id": "NCT00724061", "title": "Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Pegylated interferon α-2b", "type": "BIOLOGICAL" }, { "name": "Psoralens with ultraviolet light A", "type": "OTHER" }, { "name": "Narrowband-ultraviolet light B", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 7, "start_date": "2008-09", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2018-12-12", "last_synced_at": "2026-09-09T13:47:07.820Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00724061" }, { "nct_id": "NCT01073436", "title": "Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Discontinuation of therapy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2009-05", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2016-11-15", "last_synced_at": "2026-09-09T13:47:07.820Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01073436" } ] }